FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with…
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45…